The cell therapy field was facing one of its toughest climates when it came to investments in 2025. But, hope was not lost. The industry was rallying together to keep driving innovation in cell therapy efficacy, durability, streamlining manufacturing, potency understanding, reducing vein to vein time and navigating regulatory hurdles. For the 10^th Anniversary of the CAR-TCR Summit attendees reflected on a decade of progress whilst engaging in solutions-driven discussions that empowered them to tackle cell therapy development challenges to help shape the future of the field.

Built in collaboration with industry veterans including AstraZeneca, Cabaletta Bio, Arsenal Bio, Bristol Myers Squibb, Kyverna Therapeutics, T-knife Therapeutics, and Umoja Biopharma, this meeting equipped you to overcome challenges across the entire development landscape - spanning durability, manufacturing timelines, potency assay matrix, solid tumor targeting, biomarker data, high cost of goods, scale up and scale out, and more, to make rapid advancements in the clinic and beyond.

Whether your focus was on Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, or Analytical Development you gained in-depth insights across the entire cell therapy value chain.